Evidence map›Paper›PMID 27160900›Full record

ArticleCell reports2016

Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.

Katie A Howell, Xiangguo Qiu, Jennifer M Brannan, Christopher Bryan, Edgar Davidson, Frederick W Holtsberg, Anna Z Wec, Sergey Shulenin, Julia E Biggins, Robin Douglas and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Design of universal Ebola virus vaccine candidates via immunofocusing.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  16. Production and Purification of Filovirus Glycoproteins.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  17. Article
  18. Design of universal Ebola virus vaccine candidatesbioRxiv : the preprint server for biology · 2023
    Article
  19. Article
  20. Pseudotyped Viruses for Marburgvirus and Ebolavirus.Advances in experimental medicine and biology · 2023
    Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Katie A HowellIntegrated BioTherapeutics, Inc., Gaithersburg, MD 20878, USA.
Xiangguo QiuSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada; Deparment of Medical Microbiology, University of Manitoba, Winnipeg, MB R3E 0J9, Canada; Department of Immunology, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.
Jennifer M BrannanU.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Christopher BryanIntegral Molecular, Philadelphia, PA 19104, USA.
Edgar DavidsonIntegral Molecular, Philadelphia, PA 19104, USA.
Frederick W HoltsbergIntegrated BioTherapeutics, Inc., Gaithersburg, MD 20878, USA.
Anna Z WecDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Sergey ShuleninIntegrated BioTherapeutics, Inc., Gaithersburg, MD 20878, USA.
Julia E BigginsIntegrated BioTherapeutics, Inc., Gaithersburg, MD 20878, USA.
Robin DouglasIntegrated BioTherapeutics, Inc., Gaithersburg, MD 20878, USA.
Sven G EnterleinIntegrated BioTherapeutics, Inc., Gaithersburg, MD 20878, USA.
Hannah L TurnerDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Jesper PallesenDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Charles D MurinDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
Shihua HeSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada; Deparment of Medical Microbiology, University of Manitoba, Winnipeg, MB R3E 0J9, Canada; Department of Immunology, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.
Andrea KroekerSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada; Deparment of Medical Microbiology, University of Manitoba, Winnipeg, MB R3E 0J9, Canada; Department of Immunology, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.
Hong VuIntegrated BioTherapeutics, Inc., Gaithersburg, MD 20878, USA.
Andrew S HerbertU.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Marnie L FuscoDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
Elisabeth K NyakaturaDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Jonathan R LaiDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Zhen-Yong KeckDepartment of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Steven K H FoungDepartment of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Erica Ollmann SaphireDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Larry ZeitlinMapp Biopharmaceutical, San Diego, CA 92121, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Kartik ChandranDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Benjamin J DoranzIntegral Molecular, Philadelphia, PA 19104, USA.
Gary P KobingerSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada; Deparment of Medical Microbiology, University of Manitoba, Winnipeg, MB R3E 0J9, Canada; Department of Immunology, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.
John M DyeU.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
M Javad AmanIntegrated BioTherapeutics, Inc., Gaithersburg, MD 20878, USA. Electronic address: javad@integratedbiotherapeutics.com.

Funding

Mechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAI, JONATHAN R. · 2014 to 2018
$29.6M
NIAID NIH HHS HHSN272201400058CNIAID NIH HHS U19 AI109762
6 · The paper itself

Abstract

Previous efforts to identify cross-neutralizing antibodies to the receptor-binding site (RBS) of ebolavirus glycoproteins have been unsuccessful, largely because the RBS is occluded on the viral surface. We report a monoclonal antibody (FVM04) that targets a uniquely exposed epitope within the RBS; cross-neutralizes Ebola (EBOV), Sudan (SUDV), and, to a lesser extent, Bundibugyo viruses; and shows protection against EBOV and SUDV in mice and guinea pigs. The antibody cocktail ZMapp™ is remarkably effective against EBOV (Zaire) but does not cross-neutralize other ebolaviruses. By replacing one of the ZMapp™ components with FVM04, we retained the anti-EBOV efficacy while extending the breadth of protection to SUDV, thereby generating a cross-protective antibody cocktail. In addition, we report several mutations at the base of the ebolavirus glycoprotein that enhance the binding of FVM04 and other cross-reactive antibodies. These findings have important implications for pan-ebolavirus vaccine development and defining broadly protective antibody cocktails.

Indexed as

Amino Acid SequenceAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralBinding SitesDisease Models, AnimalEbolavirusEpitopesFemaleGlycoproteinsGuinea PigsHEK293 CellsHemorrhagic Fever, EbolaHumansKineticsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesGlycoproteinsReceptors, Virus

Identifiers

PMID27160900
PMCPMC4871745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.